Optimizing targeted therapy for metastatic melanoma: a combination of encorafenib and trametinib beyond standard protocols. Dermatol Reports [Internet]. 2025 Apr. 15 [cited 2025 Aug. 4];. Available from: https://journals.pagepress.org/dr/article/view/10036